Influence on erythropoietin levels of treatment with cisplatinum-endoxan
Erythropoietin levels have been determined in 24 patients with different gynecologic malignancies, who were treated with cisplatinum and endoxan. A statistically highly significant decrease was demonstrated 2 h after starting treatment with a further significant decrease at 6 h. After 12 h the eryth...
Gespeichert in:
| Veröffentlicht in: | Archives of gynecology and obstetrics 1992-09, Vol.252 (1), p.49-53 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 53 |
|---|---|
| container_issue | 1 |
| container_start_page | 49 |
| container_title | Archives of gynecology and obstetrics |
| container_volume | 252 |
| creator | Lechner, W Artner-Dworzak, E Sölder, E Sachsenmaier, M Kölle, D Moncayo, H Reitsamer, R |
| description | Erythropoietin levels have been determined in 24 patients with different gynecologic malignancies, who were treated with cisplatinum and endoxan. A statistically highly significant decrease was demonstrated 2 h after starting treatment with a further significant decrease at 6 h. After 12 h the erythropoietin concentrations returned to values similar to those before treatment started. |
| doi_str_mv | 10.1007/BF02389607 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF02389607</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1417088</sourcerecordid><originalsourceid>FETCH-LOGICAL-c282t-f4fa2295bb879a451afe164740ad5d931c53b595739d98e5ffee0df06d0b2bc33</originalsourceid><addsrcrecordid>eNpFkMFLwzAYxYMoc04v3oWcheqXpGmSow7nBgMvei5p-4VV2rQkmbr_fhsTdnrv8OPB-xFyz-CJAajn1wVwoU0B6oJMWS54BoqxSzIFc-xQqGtyE-M3AONaFxMyYTlToPWULFfedVv0NdLBUwy7tAnDOLSYWk87_MEu0sHRFNCmHn2iv23a0LqNY2cPyLbP0DfDn_W35MrZLuLdf87I1-Ltc77M1h_vq_nLOqu55ilzubOcG1lVWhmbS2YdsiJXOdhGNkawWopKGqmEaYxG6RwiNA6KBipe1ULMyONptw5DjAFdOYa2t2FXMiiPNsqzjQP8cILHbdVjc0ZP98Ue2tFa-w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Influence on erythropoietin levels of treatment with cisplatinum-endoxan</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Lechner, W ; Artner-Dworzak, E ; Sölder, E ; Sachsenmaier, M ; Kölle, D ; Moncayo, H ; Reitsamer, R</creator><creatorcontrib>Lechner, W ; Artner-Dworzak, E ; Sölder, E ; Sachsenmaier, M ; Kölle, D ; Moncayo, H ; Reitsamer, R</creatorcontrib><description>Erythropoietin levels have been determined in 24 patients with different gynecologic malignancies, who were treated with cisplatinum and endoxan. A statistically highly significant decrease was demonstrated 2 h after starting treatment with a further significant decrease at 6 h. After 12 h the erythropoietin concentrations returned to values similar to those before treatment started.</description><identifier>ISSN: 0932-0067</identifier><identifier>EISSN: 1432-0711</identifier><identifier>DOI: 10.1007/BF02389607</identifier><identifier>PMID: 1417088</identifier><language>eng</language><publisher>Germany</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - adverse effects ; Erythropoietin - blood ; Female ; Genital Neoplasms, Female - blood ; Genital Neoplasms, Female - drug therapy ; Humans ; Middle Aged</subject><ispartof>Archives of gynecology and obstetrics, 1992-09, Vol.252 (1), p.49-53</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c282t-f4fa2295bb879a451afe164740ad5d931c53b595739d98e5ffee0df06d0b2bc33</citedby><cites>FETCH-LOGICAL-c282t-f4fa2295bb879a451afe164740ad5d931c53b595739d98e5ffee0df06d0b2bc33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1417088$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lechner, W</creatorcontrib><creatorcontrib>Artner-Dworzak, E</creatorcontrib><creatorcontrib>Sölder, E</creatorcontrib><creatorcontrib>Sachsenmaier, M</creatorcontrib><creatorcontrib>Kölle, D</creatorcontrib><creatorcontrib>Moncayo, H</creatorcontrib><creatorcontrib>Reitsamer, R</creatorcontrib><title>Influence on erythropoietin levels of treatment with cisplatinum-endoxan</title><title>Archives of gynecology and obstetrics</title><addtitle>Arch Gynecol Obstet</addtitle><description>Erythropoietin levels have been determined in 24 patients with different gynecologic malignancies, who were treated with cisplatinum and endoxan. A statistically highly significant decrease was demonstrated 2 h after starting treatment with a further significant decrease at 6 h. After 12 h the erythropoietin concentrations returned to values similar to those before treatment started.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Erythropoietin - blood</subject><subject>Female</subject><subject>Genital Neoplasms, Female - blood</subject><subject>Genital Neoplasms, Female - drug therapy</subject><subject>Humans</subject><subject>Middle Aged</subject><issn>0932-0067</issn><issn>1432-0711</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMFLwzAYxYMoc04v3oWcheqXpGmSow7nBgMvei5p-4VV2rQkmbr_fhsTdnrv8OPB-xFyz-CJAajn1wVwoU0B6oJMWS54BoqxSzIFc-xQqGtyE-M3AONaFxMyYTlToPWULFfedVv0NdLBUwy7tAnDOLSYWk87_MEu0sHRFNCmHn2iv23a0LqNY2cPyLbP0DfDn_W35MrZLuLdf87I1-Ltc77M1h_vq_nLOqu55ilzubOcG1lVWhmbS2YdsiJXOdhGNkawWopKGqmEaYxG6RwiNA6KBipe1ULMyONptw5DjAFdOYa2t2FXMiiPNsqzjQP8cILHbdVjc0ZP98Ue2tFa-w</recordid><startdate>19920901</startdate><enddate>19920901</enddate><creator>Lechner, W</creator><creator>Artner-Dworzak, E</creator><creator>Sölder, E</creator><creator>Sachsenmaier, M</creator><creator>Kölle, D</creator><creator>Moncayo, H</creator><creator>Reitsamer, R</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19920901</creationdate><title>Influence on erythropoietin levels of treatment with cisplatinum-endoxan</title><author>Lechner, W ; Artner-Dworzak, E ; Sölder, E ; Sachsenmaier, M ; Kölle, D ; Moncayo, H ; Reitsamer, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c282t-f4fa2295bb879a451afe164740ad5d931c53b595739d98e5ffee0df06d0b2bc33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Erythropoietin - blood</topic><topic>Female</topic><topic>Genital Neoplasms, Female - blood</topic><topic>Genital Neoplasms, Female - drug therapy</topic><topic>Humans</topic><topic>Middle Aged</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lechner, W</creatorcontrib><creatorcontrib>Artner-Dworzak, E</creatorcontrib><creatorcontrib>Sölder, E</creatorcontrib><creatorcontrib>Sachsenmaier, M</creatorcontrib><creatorcontrib>Kölle, D</creatorcontrib><creatorcontrib>Moncayo, H</creatorcontrib><creatorcontrib>Reitsamer, R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Archives of gynecology and obstetrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lechner, W</au><au>Artner-Dworzak, E</au><au>Sölder, E</au><au>Sachsenmaier, M</au><au>Kölle, D</au><au>Moncayo, H</au><au>Reitsamer, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence on erythropoietin levels of treatment with cisplatinum-endoxan</atitle><jtitle>Archives of gynecology and obstetrics</jtitle><addtitle>Arch Gynecol Obstet</addtitle><date>1992-09-01</date><risdate>1992</risdate><volume>252</volume><issue>1</issue><spage>49</spage><epage>53</epage><pages>49-53</pages><issn>0932-0067</issn><eissn>1432-0711</eissn><abstract>Erythropoietin levels have been determined in 24 patients with different gynecologic malignancies, who were treated with cisplatinum and endoxan. A statistically highly significant decrease was demonstrated 2 h after starting treatment with a further significant decrease at 6 h. After 12 h the erythropoietin concentrations returned to values similar to those before treatment started.</abstract><cop>Germany</cop><pmid>1417088</pmid><doi>10.1007/BF02389607</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0932-0067 |
| ispartof | Archives of gynecology and obstetrics, 1992-09, Vol.252 (1), p.49-53 |
| issn | 0932-0067 1432-0711 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF02389607 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cisplatin - administration & dosage Cisplatin - adverse effects Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Erythropoietin - blood Female Genital Neoplasms, Female - blood Genital Neoplasms, Female - drug therapy Humans Middle Aged |
| title | Influence on erythropoietin levels of treatment with cisplatinum-endoxan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T08%3A57%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20on%20erythropoietin%20levels%20of%20treatment%20with%20cisplatinum-endoxan&rft.jtitle=Archives%20of%20gynecology%20and%20obstetrics&rft.au=Lechner,%20W&rft.date=1992-09-01&rft.volume=252&rft.issue=1&rft.spage=49&rft.epage=53&rft.pages=49-53&rft.issn=0932-0067&rft.eissn=1432-0711&rft_id=info:doi/10.1007/BF02389607&rft_dat=%3Cpubmed_cross%3E1417088%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/1417088&rfr_iscdi=true |